Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Reproducibility of Lymphovascular Space Invasion (LVSI) Assessment in Endometrial Cancer.

Peters EEM, Bartosch C, McCluggage WG, Genestie C, Lax SF, Nout R, Oosting J, Singh N, Smit HCSH, Smit VTHBM, Van de Vijver KK, Bosse T.

Histopathology. 2019 Jun 2. doi: 10.1111/his.13871. [Epub ahead of print]

PMID:
31155736
2.

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.

de Groot AF, Blok EJ, Charehbili A, Engels CC, Smit VTHBM, Dekker-Ensink NG, Putter H, Meershoek-Klein Kranenbarg E, van de Velde CJH, Liefers GJ, Nortier JWR, Kuppen PJK, van der Burg SH, Kroep JR.

Breast Cancer Res Treat. 2019 Jun;175(3):605-615. doi: 10.1007/s10549-019-05195-y. Epub 2019 Mar 13.

3.

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.

de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, Smit VTHBM, Nout RA, Glaire MA, Church DN, Vrieling H, Job B, Boursin Y, de Kroon CD, Rouleau E, Leary A, Vreeswijk MPG, Bosse T.

Clin Cancer Res. 2019 Feb 1;25(3):1087-1097. doi: 10.1158/1078-0432.CCR-18-1443. Epub 2018 Nov 9.

PMID:
30413523
4.

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.

Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group.

Br J Cancer. 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25.

PMID:
30356126
5.

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.

Wortman BG, Bosse T, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld H, van den Berg H, Slot A, De Winter KAJ, Verhoeven-Adema KW, Smit VTHBM, Creutzberg CL; PORTEC Study Group.

Gynecol Oncol. 2018 Oct;151(1):69-75. doi: 10.1016/j.ygyno.2018.07.020. Epub 2018 Aug 3.

6.

Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue.

de Jonge MM, Ruano D, van Eijk R, van der Stoep N, Nielsen M, Wijnen JT, Ter Haar NT, Baalbergen A, Bos MEMM, Kagie MJ, Vreeswijk MPG, Gaarenstroom KN, Kroep JR, Smit VTHBM, Bosse T, van Wezel T, van Asperen CJ.

J Mol Diagn. 2018 Sep;20(5):600-611. doi: 10.1016/j.jmoldx.2018.05.005. Epub 2018 Jun 21.

7.

Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.

Blok EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, Putter H, Smit VTHBM, Liefers GJ, Morden JP, Bliss JM, Coombes RC, Bartlett JMS, Kroep JR, van de Velde CJH, Kuppen PJK.

Breast Cancer Res Treat. 2018 Aug;171(1):65-74. doi: 10.1007/s10549-018-4785-z. Epub 2018 May 15.

PMID:
29766362
8.

Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.

van den Broek AJ, Schmidt MK, van 't Veer LJ, Oldenburg HSA, Rutgers EJ, Russell NS, Smit VTHBM, Voogd AC, Koppert LB, Siesling S, Jobsen JJ, Westenend PJ, van Leeuwen FE, Tollenaar RAEM.

Ann Surg. 2018 May 1. doi: 10.1097/SLA.0000000000002804. [Epub ahead of print]

PMID:
29727326
9.

E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium.

Horne HN, Oh H, Sherman ME, Palakal M, Hewitt SM, Schmidt MK, Milne RL, Hardisson D, Benitez J, Blomqvist C, Bolla MK, Brenner H, Chang-Claude J, Cora R, Couch FJ, Cuk K, Devilee P, Easton DF, Eccles DM, Eilber U, Hartikainen JM, Heikkilä P, Holleczek B, Hooning MJ, Jones M, Keeman R, Mannermaa A, Martens JWM, Muranen TA, Nevanlinna H, Olson JE, Orr N, Perez JIA, Pharoah PDP, Ruddy KJ, Saum KU, Schoemaker MJ, Seynaeve C, Sironen R, Smit VTHBM, Swerdlow AJ, Tengström M, Thomas AS, Timmermans AM, Tollenaar RAEM, Troester MA, van Asperen CJ, van Deurzen CHM, Van Leeuwen FF, Van't Veer LJ, García-Closas M, Figueroa JD.

Sci Rep. 2018 Apr 26;8(1):6574. doi: 10.1038/s41598-018-23733-4.

10.

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.

Temko D, Van Gool IC, Rayner E, Glaire M, Makino S, Brown M, Chegwidden L, Palles C, Depreeuw J, Beggs A, Stathopoulou C, Mason J, Baker AM, Williams M, Cerundolo V, Rei M, Taylor JC, Schuh A, Ahmed A, Amant F, Lambrechts D, Smit VT, Bosse T, Graham TA, Church DN, Tomlinson I.

J Pathol. 2018 Jul;245(3):283-296. doi: 10.1002/path.5081. Epub 2018 Apr 30.

11.

Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues.

Van Gool IC, Rayner E, Osse EM, Nout RA, Creutzberg CL, Tomlinson IPM, Church DN, Smit VTHBM, de Wind N, Bosse T, Drost M.

Clin Cancer Res. 2018 Jul 1;24(13):3197-3203. doi: 10.1158/1078-0432.CCR-18-0266. Epub 2018 Mar 20.

PMID:
29559562
12.

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

13.

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.

Severson TM, Kim Y, Joosten SEP, Schuurman K, van der Groep P, Moelans CB, Ter Hoeve ND, Manson QF, Martens JW, van Deurzen CHM, Barbe E, Hedenfalk I, Bult P, Smit VTHBM, Linn SC, van Diest PJ, Wessels L, Zwart W.

Nat Commun. 2018 Feb 2;9(1):482. doi: 10.1038/s41467-018-02856-2.

14.

Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma.

Vangangelt KMH, van Pelt GW, Engels CC, Putter H, Liefers GJ, Smit VTHBM, Tollenaar RAEM, Kuppen PJK, Mesker WE.

Breast Cancer Res Treat. 2018 Apr;168(3):601-612. doi: 10.1007/s10549-017-4617-6. Epub 2017 Dec 22.

15.

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.

de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; for PORTEC Study Group.

Ann Oncol. 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753.

16.

Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe.

Blok EJ, Bastiaannet E, van den Hout WB, Liefers GJ, Smit VTHBM, Kroep JR, van de Velde CJH.

Cancer Treat Rev. 2018 Jan;62:74-90. doi: 10.1016/j.ctrv.2017.10.012. Epub 2017 Nov 6. Review.

17.

Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance.

Nooij LS, Ter Haar NT, Ruano D, Rakislova N, van Wezel T, Smit VTHBM, Trimbos BJBMZ, Ordi J, van Poelgeest MIE, Bosse T.

Clin Cancer Res. 2017 Nov 15;23(22):6781-6789. doi: 10.1158/1078-0432.CCR-17-1302. Epub 2017 Sep 12.

18.

A novel keratin 13 variant in a four-generation family with white sponge nevus.

de Haseth SB, Bakker E, Vermeer MH, El Idrissi H, Bosse T, Smit VTHBM, Terron-Kwiatkowski A, McLean WHI, Peters AAW, Hes FJ.

Clin Case Rep. 2017 Jul 29;5(9):1503-1509. doi: 10.1002/ccr3.1073. eCollection 2017 Sep.

19.

Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia.

Majoor BC, Boyce AM, Bovée JV, Smit VT, Collins MT, Cleton-Jansen AM, Dekkers OM, Hamdy NA, Dijkstra PS, Appelman-Dijkstra NM.

J Bone Miner Res. 2018 Jan;33(1):84-90. doi: 10.1002/jbmr.3286. Epub 2017 Sep 20.

20.

Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.

Van Gool IC, Ubachs JEH, Stelloo E, de Kroon CD, Goeman JJ, Smit VTHBM, Creutzberg CL, Bosse T.

Histopathology. 2018 Jan;72(2):248-258. doi: 10.1111/his.13338. Epub 2017 Oct 10.

PMID:
28795426
21.

The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study.

Roeke T, Sobral-Leite M, Dekker TJA, Wesseling J, Smit VTHBM, Tollenaar RAEM, Schmidt MK, Mesker WE.

Breast Cancer Res Treat. 2017 Nov;166(2):435-445. doi: 10.1007/s10549-017-4445-8. Epub 2017 Aug 9.

PMID:
28795248
22.

Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.

van Esterik M, Van Gool IC, de Kroon CD, Nout RA, Creutzberg CL, Smit VTHBM, Bosse T, Stelloo E.

Oncotarget. 2017 Apr 11;8(15):25542-25551. doi: 10.18632/oncotarget.16067.

23.

Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.

Engelhardt EG, van den Broek AJ, Linn SC, Wishart GC, Rutgers EJT, van de Velde AO, Smit VTHBM, Voogd AC, Siesling S, Brinkhuis M, Seynaeve C, Westenend PJ, Stiggelbout AM, Tollenaar RAEM, van Leeuwen FE, van 't Veer LJ, Ravdin PM, Pharaoh PDP, Schmidt MK.

Eur J Cancer. 2017 Jun;78:37-44. doi: 10.1016/j.ejca.2017.03.015. Epub 2017 Apr 14.

PMID:
28412587
24.

Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.

Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, Oosterhuis WJ, Wesseling J, Janssen-Heijnen ML, Jobsen JJ, Jager A, Voogd AC, van Leeuwen FE, van 't Veer LJ.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw329.

PMID:
28376189
25.

Morphological and phenotypical features of ovarian metastases in breast cancer patients.

Peters IT, van der Steen MA, Huisman BW, Hilders CG, Smit VT, Vahrmeijer AL, Sier CF, Trimbos JB, Kuppen PJ.

BMC Cancer. 2017 Mar 21;17(1):206. doi: 10.1186/s12885-017-3191-y.

26.

Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.

Peters IT, van Zwet EW, Smit VT, Liefers GJ, Kuppen PJ, Hilders CG, Trimbos JB.

PLoS One. 2017 Jan 26;12(1):e0168277. doi: 10.1371/journal.pone.0168277. eCollection 2017.

27.

Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.

Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EH, van den Berg JH, Haanen JB, Smit VT, Oosting J, van der Burg SH, Verdegaal EM.

Cancer Immunol Res. 2017 Feb;5(2):170-179. doi: 10.1158/2326-6066.CIR-16-0288. Epub 2017 Jan 10.

28.

Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.

de Jonge MM, Mooyaart AL, Vreeswijk MP, de Kroon CD, van Wezel T, van Asperen CJ, Smit VT, Dekkers OM, Bosse T.

Eur J Cancer. 2017 Feb;72:215-225. doi: 10.1016/j.ejca.2016.11.028. Epub 2016 Dec 31. Review.

PMID:
28049106
29.

70-Gene Signature in Early-Stage Breast Cancer.

Blok EJ, van de Velde CJ, Smit VT.

N Engl J Med. 2016 Dec 1;375(22):2199. doi: 10.1056/NEJMc1612048. No abstract available.

PMID:
27959763
30.

Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer.

Stelloo E, Versluis MA, Nijman HW, de Bruyn M, Plat A, Osse EM, van Dijk RH, Nout RA, Creutzberg CL, de Bock GH, Smit VT, Bosse T, Hollema H.

Oncotarget. 2016 Jun 28;7(26):39885-39893. doi: 10.18632/oncotarget.9414.

31.

Practical guidance for mismatch repair-deficiency testing in endometrial cancer.

Stelloo E, Jansen AML, Osse EM, Nout RA, Creutzberg CL, Ruano D, Church DN, Morreau H, Smit VTHBM, van Wezel T, Bosse T.

Ann Oncol. 2017 Jan 1;28(1):96-102. doi: 10.1093/annonc/mdw542.

PMID:
27742654
32.

Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter?

Nooij LS, van der Slot MA, Dekkers OM, Stijnen T, Gaarenstroom KN, Creutzberg CL, Smit VT, Bosse T, van Poelgeest MI.

Eur J Cancer. 2016 Sep;65:139-49. doi: 10.1016/j.ejca.2016.07.006. Epub 2016 Aug 3. Review.

PMID:
27497345
33.

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7.

34.

A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer.

Hoogstins CE, Tummers QR, Gaarenstroom KN, de Kroon CD, Trimbos JB, Bosse T, Smit VT, Vuyk J, van de Velde CJ, Cohen AF, Low PS, Burggraaf J, Vahrmeijer AL.

Clin Cancer Res. 2016 Jun 15;22(12):2929-38. doi: 10.1158/1078-0432.CCR-15-2640.

35.

Stathmin is a highly sensitive and specific biomarker for vulvar high-grade squamous intraepithelial lesions.

Nooij LS, Dreef EJ, Smit VT, van Poelgeest MI, Bosse T.

J Clin Pathol. 2016 Dec;69(12):1070-1075. doi: 10.1136/jclinpath-2016-203676. Epub 2016 May 25.

PMID:
27226646
36.

Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17.

Tummers QR, Hoogstins CE, Gaarenstroom KN, de Kroon CD, van Poelgeest MI, Vuyk J, Bosse T, Smit VT, van de Velde CJ, Cohen AF, Low PS, Burggraaf J, Vahrmeijer AL.

Oncotarget. 2016 May 31;7(22):32144-55. doi: 10.18632/oncotarget.8282.

37.

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.

Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT.

Clin Cancer Res. 2016 Aug 15;22(16):4215-24. doi: 10.1158/1078-0432.CCR-15-2878. Epub 2016 Mar 22.

38.

The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.

Engels CC, Kiderlen M, Bastiaannet E, van Eijk R, Mooyaart A, Smit VT, de Craen AJ, Kuppen PJ, Kroep JR, van de Velde CJ, Liefers GJ.

Breast Cancer Res Treat. 2016 Apr;156(2):361-70. doi: 10.1007/s10549-016-3734-y. Epub 2016 Mar 11.

39.

Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue.

Peters IT, Hilders CG, Sier CF, Vahrmeijer AL, Smit VT, Baptist Trimbos J, Kuppen PJ.

Arch Gynecol Obstet. 2016 Aug;294(2):385-93. doi: 10.1007/s00404-016-4036-7. Epub 2016 Mar 5.

40.

Exploring Morphologic and Molecular Aspects of Endometrial Cancer Under Progesterone Treatment in the Context of Fertility Preservation.

van Gent MD, Nicolae-Cristea AR, de Kroon CD, Osse EM, Kagie MJ, Trimbos JB, Hazelbag HM, Smit VT, Bosse T.

Int J Gynecol Cancer. 2016 Mar;26(3):483-90. doi: 10.1097/IGC.0000000000000629.

PMID:
26825822
41.

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.

Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, MacKay HJ, Leary A, Powell ME, Mileshkin L, Creutzberg CL, Smit VT, Bosse T.

Mod Pathol. 2016 Feb;29(2):174-81. doi: 10.1038/modpathol.2015.147. Epub 2016 Jan 8.

42.

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group.

Breast Cancer Res. 2016 Jan 6;18(1):3. doi: 10.1186/s13058-015-0663-3.

43.

The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: A FOCUS study analysis.

Engels CC, Kiderlen M, Bastiaannet E, Mooyaart AL, van Vlierberghe R, Smit VT, Kuppen PJ, van de Velde CJ, Liefers GJ.

Mol Oncol. 2016 Apr;10(4):594-600. doi: 10.1016/j.molonc.2015.11.002. Epub 2015 Nov 24.

44.

The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis.

Engels CC, de Glas NA, Sajet A, Bastiaannet E, Smit VT, Kuppen PJ, Seynaeve C, van de Velde CJ, Liefers GJ.

Mol Oncol. 2016 Apr;10(4):509-16. doi: 10.1016/j.molonc.2015.10.010. Epub 2015 Oct 31.

45.

Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.

van den Broek AJ, van 't Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, van Beek M, Janssen-Heijnen ML, Seynaeve C, Westenend PJ, Jobsen JJ, Siesling S, Tollenaar RA, van Leeuwen FE, Schmidt MK.

J Clin Oncol. 2016 Feb 10;34(5):409-18. doi: 10.1200/JCO.2015.62.3942. Epub 2015 Dec 23.

PMID:
26700119
46.

Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).

Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van der Hoeven JJ, van de Velde CJ, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG).

Breast. 2016 Feb;25:69-74. doi: 10.1016/j.breast.2015.10.005. Epub 2015 Nov 21.

PMID:
26614548
47.

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH.

Oncotarget. 2015 Oct 13;6(31):32228-43. doi: 10.18632/oncotarget.4772.

48.

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters.

Versluis MA, de Jong RA, Plat A, Bosse T, Smit VT, Mackay H, Powell M, Leary A, Mileshkin L, Kitchener HC, Crosbie EJ, Edmondson RJ, Creutzberg CL, Hollema H, Daemen T, de Bock GH, Nijman HW.

Br J Cancer. 2015 Sep 1;113(5):786-93. doi: 10.1038/bjc.2015.268. Epub 2015 Jul 28.

49.

Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis.

Sobral-Leite M, Wesseling J, Smit VT, Nevanlinna H, van Miltenburg MH, Sanders J, Hofland I, Blows FM, Coulson P, Patrycja G, Schellens JH, Fagerholm R, Heikkilä P, Aittomäki K, Blomqvist C, Provenzano E, Ali HR, Figueroa J, Sherman M, Lissowska J, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Phillips KA; kConFab/AOCS Investigators, Couch FJ, Olson JE, Vachon C, Visscher D, Brenner H, Butterbach K, Arndt V, Holleczek B, Hooning MJ, Hollestelle A, Martens JW, van Deurzen CH, van de Water B, Broeks A, Chang-Claude J, Chenevix-Trench G, Easton DF, Pharoah PD, García-Closas M, de Graauw M, Schmidt MK.

BMC Med. 2015 Jul 2;13:156. doi: 10.1186/s12916-015-0392-6.

50.

Erratum to: Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach.

Dekker TJ, ter Borg S, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Bult P, Riemersma SA, van Deurzen CH, Sleddens HF, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ.

Breast Cancer Res Treat. 2015 Jul;152(2):253. doi: 10.1007/s10549-015-3478-0. No abstract available.

Supplemental Content

Support Center